FDA, Boehringer Disagree On Non-Inferiority Margin For Micardis Prophylaxis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will tell advisory committee that non-inferiority analysis should account for improvements in standard of care that change effect size.